What are analysts'target prices for Atara Biotherapeutics'stock?
6 brokerages have issued 1-year target prices for Atara Biotherapeutics' stock. Their forecasts range from $27.00 to $41.00. On average, they expect Atara Biotherapeutics' stock price to reach $31.00 in the next year. This suggests a possible upside of 89.6% from the stock's current price.
What is the upside for Atara Biotherapeutics'stock?
Their forecasts range from $27.00 to $41.00. On average, they expect Atara Biotherapeutics' stock price to reach $31.00 in the next year. This suggests a possible upside of 89.6% from the stock's current price. View analysts' price targets for Atara Biotherapeutics or view top-rated stocks among Wall Street analysts.
Where can I buy shares of ATRA?
Shares of ATRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
Who sold Atatra stock in the last quarter?
ATRA stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Dimensional Fund Advisors LP, Bridger Management LLC, Credit Suisse AG, Alberta Investment Management Corp, Millennium Management LLC, Two Sigma Investments LP, and Morgan Stanley.
Is Atara stock a buy?
The 8 analysts offering 12-month price forecasts for Atara Biotherapeutics Inc have a median target of 17.00, with a high estimate of 50.00 and a low estimate of 3.00. The median estimate represents a +439.68% increase from the last price of 3.15.
Is Atara publicly traded?
Atara Biotherapeutics is traded on the NASDAQ stock exchange under the symbol “ATRA”.
Should I buy ATRA stock?
The financial health and growth prospects of ATRA, demonstrate its potential to underperform the market. It currently has a Growth Score of D. Recent price changes and earnings estimate revisions indicate this would be a good stock for momentum investors with a Momentum Score of A.
Why did Atara stock drop?
What happened. Shares of the clinical-stage cell therapy company Atara Biotherapeutics (ATRA -2.93%) are under heavy pressure today following a fatality in an ongoing, early-stage dose escalation trial. In response to this clinical setback, the biotech's shares were down by a hefty 12% as of 9:49 a.m. ET Friday morning ...
What is ATA188?
Our T cell immunotherapy product candidate, ATA188, is an off-the-shelf, allogeneic EBV T cell that utilizes a targeted antigen recognition technology that enables the T cells we administer to selectively identify cells expressing the EBV antigens that may be important in the pathophysiology of MS.
Should I buy or sell Atara Biotherapeutics stock right now?
6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Atara Biotherapeutics in the last year. There are currently 1 sel...
What is Atara Biotherapeutics' stock price forecast for 2022?
6 Wall Street analysts have issued twelve-month target prices for Atara Biotherapeutics' stock. Their ATRA stock forecasts range from $4.00 to $67....
How has Atara Biotherapeutics' stock price performed in 2022?
Atara Biotherapeutics' stock was trading at $15.76 at the start of the year. Since then, ATRA shares have decreased by 66.9% and is now trading at...
When is Atara Biotherapeutics' next earnings date?
Atara Biotherapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022. View our earnings forecast for...
How were Atara Biotherapeutics' earnings last quarter?
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) announced its quarterly earnings data on Thursday, May, 5th. The biotechnology company reported ($0.87) E...
Who are Atara Biotherapeutics' key executives?
Atara Biotherapeutics' management team includes the following people: Dr. Pascal Touchon D.V.M. , Pres, CEO & Director (Age 59, Pay $1.09M) Mr....
What is Pascal Touchon's approval rating as Atara Biotherapeutics' CEO?
6 employees have rated Atara Biotherapeutics CEO Pascal Touchon on Glassdoor.com . Pascal Touchon has an approval rating of 60% among Atara Biothe...
Who are some of Atara Biotherapeutics' key competitors?
Some companies that are related to Atara Biotherapeutics include Fate Therapeutics (FATE) , BioCryst Pharmaceuticals (BCRX) , Exscientia (EXAI)...
What other stocks do shareholders of Atara Biotherapeutics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Atara Biotherapeutics investors own include CRISPR Therape...
About Atara Biotherapeutics
Atara Biotherapeutics (NASDAQ:ATRA) Frequently Asked Questions
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. also delivers off-the-shelf treatments to patients with high unmet medical need.
What is Atara Biotherapeutics?
6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Atara Biotherapeutics in the last year. There are currently 6 buy ratings for the stock.
What time do you trade in the pre market?
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing therapeutics for patients with serious life-threatening such as cancer, autoimmune and other viral diseases. The company achieves this through two groups of product candidates, such as allogenic or third-party derived antigen-specific T-cells and molecularly targeted biologics.
Does market cap include convertible securities?
Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these sessions may offer less liquidity and inferior prices. Stock prices may also move more quickly in this environment.
What is transparency in investing?
It does not include securities convertible into the common equity securities. "Market Cap" is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities (as applicable).
What is Atara Biotherapeutics?
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
Does Morningstar cover ratings?
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing therapeutics for patients with serious life-threatening such as cancer, autoimmune and other viral diseases. The company achieves this through two groups of product candidates, such as allogenic or third-party derived antigen-specific T-cells and molecularly targeted biologics.
